Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.00
NAS:AMRN's Cash to Debt is ranked lower than
82% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. NAS:AMRN: 1.00 )
Ranked among companies with meaningful Cash to Debt only.
NAS:AMRN' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: N/A Max: No Debt
Current: 1
Equity to Asset 0.08
NAS:AMRN's Equity to Asset is ranked lower than
90% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:AMRN: 0.08 )
Ranked among companies with meaningful Equity to Asset only.
NAS:AMRN' s Equity to Asset Range Over the Past 10 Years
Min: -1.11  Med: -0.13 Max: 1
Current: 0.08
-1.11
1
F-Score: 5
Z-Score: -5.43
M-Score: -1.90
WACC vs ROIC
12.94%
-841.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -60.49
NAS:AMRN's Operating margin (%) is ranked higher than
54% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. NAS:AMRN: -60.49 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:AMRN' s Operating margin (%) Range Over the Past 10 Years
Min: -6232.2  Med: -434.06 Max: -60.49
Current: -60.49
-6232.2
-60.49
Net-margin (%) -68.45
NAS:AMRN's Net-margin (%) is ranked higher than
51% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. NAS:AMRN: -68.45 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:AMRN' s Net-margin (%) Range Over the Past 10 Years
Min: -5384  Med: -385.87 Max: -68.45
Current: -68.45
-5384
-68.45
ROA (%) -47.51
NAS:AMRN's ROA (%) is ranked lower than
65% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. NAS:AMRN: -47.51 )
Ranked among companies with meaningful ROA (%) only.
NAS:AMRN' s ROA (%) Range Over the Past 10 Years
Min: -549.69  Med: -66.15 Max: -26.61
Current: -47.51
-549.69
-26.61
ROC (Joel Greenblatt) (%) -9340.30
NAS:AMRN's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. NAS:AMRN: -9340.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:AMRN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -231547.22  Med: -8240.48 Max: -1754.58
Current: -9340.3
-231547.22
-1754.58
EBITDA Growth (3Y)(%) -18.30
NAS:AMRN's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:AMRN: -18.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:AMRN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -20.9 Max: 85.1
Current: -18.3
0
85.1
EPS Growth (3Y)(%) -12.50
NAS:AMRN's EPS Growth (3Y)(%) is ranked lower than
59% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NAS:AMRN: -12.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:AMRN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.1  Med: -15.9 Max: 156
Current: -12.5
-81.1
156
» NAS:AMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

AMRN Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q4 2015

AMRN Guru Trades in Q4 2015

Jim Simons 264,900 sh (New)
» More
Q1 2016

AMRN Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q3 2016

AMRN Guru Trades in Q3 2016

Paul Tudor Jones 29,802 sh (New)
Jim Simons 50,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with AMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:WVE, NAS:ADRO, NAS:INSM, NAS:INSY, NAS:ZIOP, NAS:ACOR, NAS:MGNX, NAS:MACK, NAS:CORT, NAS:BPMC, OTCPK:IPHYF, NAS:TBRA, NAS:AIMT, NAS:FWP, NAS:BGNE, OTCPK:PFSCF, NAS:RPTP, NAS:PTLA, NAS:VNDA, OTCPK:BPMUF » details
Traded in other countries:EH3A.Germany,
Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The Company is engaged in commercialization and development of therapeutics to improve cardiovascular health.

Amarin Corp PLC, formerly known as Ethical Holdings plc was incorporated under the laws of England and Wales on March 1, 1989 under the Companies Act 1985. It is a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company's product Vascepa (icosapent ethyl) capsules is approved by the U.S. Food and Drug Administration for the use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG>500mg/dL) hypertriglyceridemia. On January 28, 2013 the Company commenced full commercial launch of Vascepa. The Company refers to its second indication for Vascepa as the ANCHOR indication. The FDA views the proposed ANCHOR indication as ostensibly and impliedly an indication to reduce cardiovascular risk. In addition, in December 2011, the Company announced commencement of patient dosing in cardiovascular outcomes study of Vascepa, titled REDUCE-IT or Reduction of Cardiovascular Events with EPA-Intervention Trial. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing cardiovascular events in a high risk patient population on statin therapy. On January 28, 2013, the Company commenced full commercial launch of Vascepa in the United States for use in the MARINE indication. The Company now markets Vascepa in the United States through sales force of approximately 150 sales professionals and also employed marketing and medical affairs personnel to support commercialization of Vascepa. As of February 1, 2014, over 16,000 clinicians had written prescriptions for Vascepa. In November 2010, the Company reported top-line data for the MARINE trial. Vascepa was well tolerated in the MARINE trial, with a safety profile comparable to placebo and there were no treatment-related serious adverse events observed. The Company uses third party manufacturers and suppliers to manufacture clinical and commercial quantities of ethyl-EPA, which constitutes the only active pharmaceutical ingredient within Vascepa, to encapsulate, bottle and package Vascepa and to maintain inventory of Vascepa. The Company currently relies on Patheon for the encapsulation of Vascepa. The Companies competitors include GlaxoSmithKline plc and AbbVie, Inc., and Niaspan. The Company is subject to regulation by government authorities, including FDA.

Ratios

vs
industry
vs
history
P/S 5.06
AMRN's P/S is ranked higher than
72% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. AMRN: 5.06 )
Ranked among companies with meaningful P/S only.
AMRN' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 277 Max: 3900
Current: 5.06
2.8
3900
Current Ratio 2.15
AMRN's Current Ratio is ranked lower than
73% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. AMRN: 2.15 )
Ranked among companies with meaningful Current Ratio only.
AMRN' s Current Ratio Range Over the Past 10 Years
Min: 0.27  Med: 3.68 Max: 35.14
Current: 2.15
0.27
35.14
Quick Ratio 1.88
AMRN's Quick Ratio is ranked lower than
72% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. AMRN: 1.88 )
Ranked among companies with meaningful Quick Ratio only.
AMRN' s Quick Ratio Range Over the Past 10 Years
Min: 0.22  Med: 3.68 Max: 35.14
Current: 1.88
0.22
35.14
Days Inventory 224.20
AMRN's Days Inventory is ranked lower than
74% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 129.09 vs. AMRN: 224.20 )
Ranked among companies with meaningful Days Inventory only.
AMRN' s Days Inventory Range Over the Past 10 Years
Min: 214.21  Med: 311.3 Max: 650.68
Current: 224.2
214.21
650.68
Days Sales Outstanding 54.13
AMRN's Days Sales Outstanding is ranked higher than
57% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. AMRN: 54.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.49  Med: 57.27 Max: 1180.41
Current: 54.13
50.49
1180.41
Days Payable 76.86
AMRN's Days Payable is ranked higher than
61% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.68 vs. AMRN: 76.86 )
Ranked among companies with meaningful Days Payable only.
AMRN' s Days Payable Range Over the Past 10 Years
Min: 76.86  Med: 151.9 Max: 195.34
Current: 76.86
76.86
195.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.90
AMRN's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. AMRN: -6.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMRN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -271.2  Med: -54.7 Max: 21.2
Current: -6.9
-271.2
21.2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.02
AMRN's Price/Median PS Value is ranked higher than
100% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AMRN: 0.02 )
Ranked among companies with meaningful Price/Median PS Value only.
AMRN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.02 Max: 4.86
Current: 0.02
0.01
4.86
Earnings Yield (Greenblatt) (%) -7.87
AMRN's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. AMRN: -7.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMRN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -8.11  Med: 501.9 Max: 7646.9
Current: -7.87
-8.11
7646.9

More Statistics

Revenue (TTM) (Mil) $118.0
EPS (TTM) $ -0.43
Beta1.86
Short Percentage of Float1.96%
52-Week Range $1.24 - 3.65
Shares Outstanding (Mil)269.95

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 132 202 385 531
EPS ($) -0.46 -0.20 0.21 0.61
EPS w/o NRI ($) -0.46 -0.20 0.21 0.61
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for AMRN

Headlines

Articles On GuruFocus.com
Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows May 23 2014 
Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN Jan 07 2013 
Steven Cohen Adds Amarin Corp. Awaiting Drug Approval, Buys Hyatt Hotels Mar 28 2012 
Soros Funds’ Great Britain Buys and Sells Apr 13 2011 

More From Other Websites
Amarin (AMRN): Strong Industry, Solid Earnings Estimate Revisions Dec 02 2016
ETFs with exposure to Amarin Corp. Plc : November 29, 2016 Nov 29 2016
The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3 Nov 24 2016
Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
Pure EPA Vascepa® (icosapent ethyl) Showed Reductions in Potentially Atherogenic Lipid and... Nov 14 2016
Pure EPA Vascepa® (icosapent ethyl) Showed Reductions in Potentially Atherogenic Lipid and... Nov 14 2016
Amarin to Present at the Jefferies 2016 London Healthcare Conference Nov 11 2016
AMARIN CORP PLC\UK Financials Nov 09 2016
Q3 2016 Amarin Corporation PLC Earnings Release - Before Market Open Nov 03 2016
AMARIN CORP PLC\UK Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 03 2016
Amarin Reports Third Quarter 2016 Financial Results and Provides Update on Operations Nov 03 2016
Amarin reports 3Q loss Nov 03 2016
Amarin reports 3Q loss Nov 03 2016
Amarin Reports Third Quarter 2016 Financial Results and Provides Update on Operations Nov 03 2016
Investor Calendar Invites You to the Amarin Third Quarter 2016 Earnings Conference Call and Webcast... Nov 02 2016
Amarin to Report Third Quarter 2016 Results and Host Conference Call on November 3, 2016 Oct 27 2016
Amarin to Report Third Quarter 2016 Results and Host Conference Call on November 3, 2016 Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)